Anisomycin

Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. Anisomycin is a JNK activator, which increases phospho-JNK. Anisomycin is a bacterial antibiotic isolated from Streptomyces griseolus.

Product information

CAS Number: 22862-76-6

Molecular Weight: 265.30

Formula: C14H19NO4

Synonym:

Flagecidin

Wuningmeisu C

Chemical Name: (2R, 3S, 4S)-4-hydroxy-2-[(4-methoxyphenyl)methyl]pyrrolidin-3-yl acetate

Smiles: CC(=O)O[C@@H]1[C@@H](O)CN[C@@H]1CC1C=CC(=CC=1)OC

InChiKey: YKJYKKNCCRKFSL-RDBSUJKOSA-N

InChi: InChI=1S/C14H19NO4/c1-9(16)19-14-12(15-8-13(14)17)7-10-3-5-11(18-2)6-4-10/h3-6,12-15,17H,7-8H2,1-2H3/t12-,13+,14+/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 50 mg/mL (188.46 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

To examine whether JNK has a core role in colistin-induced neurotoxicity in PC-12 cells, an SP600125 (a highly selective inhibitor of JNK) and Anisomycin (a potent activator) are used in this study. In order to select an appropriate concentration, PC-12 cells are treated with a range of SP600125 (0-80 μM) and Anisomycin (0-20 μM) respectively for 24 h. The results show that the cells viability significantly decreases by SP600125 treatment in a concentration-dependent manner, observed at the concentrations greater than 20 μM (p<0.01). Similarly the cells viability is inhibited by Anisomycin treatment (≥8 μM) (p<0.05).

In Vivo:

Anisomycin (60 mg/kg; for 4-week continuous intravenous administration) significantly decreases mouse body weight in a dose-related manner, compared with the control group. Anisomycin (15 mg/kg; for 4-week continuous intravenous administration) slightly and transiently decreases the mouse body weight. There is no significant difference of the mouse body weight in 5 mg/kg group.

References:

1. Lu Z, et al. Colistin-induced autophagy and apoptosis involves the JNK-Bcl2-Bax signaling pathway and JNK-p53-ROS positive feedback loop in PC-12 cells.
2. Gao X, et al. Transcriptional regulation of stress kinase JNK2 in pro-arrhythmic CaMKIIδ expression in the aged atrium. Cardiovasc Res. 2018 Apr 1;114(5):737-746.
3. Zhengle Tang, et al. In vivo toxicological evaluation of Anisomycin. Toxicol Lett. 2012 Jan 5;208(1):1-11.
4. Synthesis Marina Macías-Silva, et al. Anisomycin is a Multifunctional Drug: More than Just a Tool to Inhibit Protein. Current Chemical Biology, 2010, 4, 124-132.

Products are for research use only. Not for human use.